Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Adams

Clinical Genetics (M.D.) Saginaw, MI Medical Doctor

NPI 1427090448 CMS profile 246471

5400 MacKinaw Rd, Suite 2300, Saginaw, MI 48604

Open in the dashboard

General payments

$84,502

135 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Adams of Saginaw, MI is reported in the CMS Open Payments database as having received $84,502 across 135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Clinical Genetics (M.D.) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,068 8
2024 General $9,880 15
2023 General $17,327 15
2022 General $15,178 26
2021 General $14,415 15
2020 General $8,378 12
2019 General $9,255 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Adams
  • Clinical Genetics (M.D.) median
  • Middle half of Clinical Genetics (M.D.)
  • National median

In program year 2025, general payments to Mark Adams were reported at $10,068. Among 315 Clinical Genetics (M.D.) profiles paid that year, the median was $255 and the middle half received between $85 and $3,583.

Show as a table
Year Mark Adams Clinical Genetics (M.D.) median Middle half National median
2019 $9,255 $130 $24–$2,691 $163
2020 $8,378 $126 $30–$3,700 $114
2021 $14,415 $185 $30–$3,777 $132
2022 $15,178 $136 $44–$2,749 $149
2023 $17,327 $196 $55–$5,220 $160
2024 $9,880 $165 $46–$3,171 $164
2025 $10,068 $255 $85–$3,583 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Globus Medical, Inc. $81,783 31 payments
  2. Boston Scientific Corporation $477 15 payments
  3. Medtronic USA, Inc. $454 23 payments
  4. Stryker Corporation $312 10 payments
  5. Abbott Laboratories $219 10 payments
  6. DePuy Synthes Sales Inc. $185 7 payments
  7. Medtronic, Inc. $177 8 payments
  8. Mizuho America, Inc. $111 1 payment
  9. Nonin Medical, Inc. $99 1 payment
  10. Zimmer Biomet Holdings, Inc. $95 2 payments
  11. Other $591 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $73,269 20 payments
  2. Consulting Fee $5,600 2 payments
  3. Food and Beverage $2,928 111 payments
  4. Travel and Lodging $2,705 2 payments
Products named General payments · program years 2019–2025
  1. Extreme Angle Cervical Plate Spine $31,020 8 payments
  2. RESONATE Spine/Spine Surgery $26,391 7 payments
  3. Extreme Angle Cervical Plate Spine/Joint $14,201 4 payments
  4. RESONATE Spine/Spine Surgery $9,960 4 payments
  5. WaveWriter Alpha Prime 16 $357 12 payments
  6. MazorX - Renaissance $118 5 payments
  7. Nonin Oximetry $99 1 payment
  8. INTELLIS $94 1 payment
  9. PROCLAIM $87 3 payments
  10. ExcelsiusGPS Robotic Navigation System $86 1 payment
  11. Other $2,089 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

146

Median for Neurosurgery: 83

Drug cost

$1,250

Median for Neurosurgery: $872

Branded share of claims

71.9%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 60 $571
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 45 $530
Cyclobenzaprine Hcl Generic 41 $150

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$194,328

Medicare's payments for the services billed

Medicare patients

399

Average age 73

Services billed

828

218 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 36%
Ischemic heart disease 35%
Diabetes 34%
COPD 28%
Chronic kidney disease 27%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Genetics (M.D.) in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record